Literature DB >> 22970668

Nasal continuous positive airway pressure for respiratory distress in non-tertiary care centres: what is needed and where to from here?

Adam Buckmaster1.   

Abstract

Respiratory distress is one of the commonest reasons for admission to a special care nursery (SCN) affecting between 2.5 and 5.0% of all babies born per year. While most recover with supplemental oxygen, some require transfer to a neonatal intensive care leading to significant family disruption, and financial cost. Does nasal continuous positive airway pressure (nCPAP) improve outcomes in babies with respiratory distress? What are the risks of its use? Should it be used in SCNs, and, if so, what is required in order to undertake nCPAP safely? There is strong evidence to support the use of nCPAP in the treatment of babies with respiratory distress. The risk benefit ratio of providing nCPAP in SCNs depends upon many factors including the ability to maintain the skills required and the distance/time to the nearest tertiary centre. Appropriate nurseries should be identified with the aim of supporting them in the provision of nCPAP in a safe manner.
© 2012 The Author. Journal of Paediatrics and Child Health © 2012 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Mesh:

Year:  2012        PMID: 22970668     DOI: 10.1111/j.1440-1754.2012.02537.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  2 in total

1.  Development and validation of a simple algorithm for initiation of CPAP in neonates with respiratory distress in Malawi.

Authors:  Shilpa G Hundalani; Rebecca Richards-Kortum; Maria Oden; Kondwani Kawaza; Alfred Gest; Elizabeth Molyneux
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2015-04-15       Impact factor: 5.747

2.  Outcome of Respiratory Distress in Neonates with Bubble CPAP at Neonatal Intensive Care Unit of a Tertiary Hospital.

Authors:  Sunil Raja Manandhar
Journal:  JNMA J Nepal Med Assoc       Date:  2019 Mar-Apr       Impact factor: 0.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.